Search
pegozafermin
Indications:
- treatment of nonalcoholic steatohepatitis (NASH)
Dosage:
- 15 mg or 30 mg SC weekly
- 44 mg SC every other week
Adverse effects:
- diarrhea, nausea
Mechanism of action:
- fibroblast growth factor 21 (FGF21) analogue
- FGF21 has favorable metabolic effects in the liver
General
gastrointestinal agent
References
- Loomba R et al.
Randomized, controlled trial of the FGF21 analogue pegozafermin in NASH.
N Engl J Med 2023 Sep 14; 389:998.
PMID: 37356033 PMCID: PMC10718287 (available on 2024-03-14)
https://www.nejm.org/doi/10.1056/NEJMoa2304286